Communiqués Bio-Thera Solutions, Ltd.

Actions

688177

CNE100003R98

Recherche biotechnologique et médicale

Cours en clôture Shanghai S.E. Autres places de cotation 11/05/2026			Varia. 5j.	Varia. 1 janv.
20,35 ^CNY	+1,55%		-1,21%	-12,06%

27/04	Bio-Thera Solutions, Ltd. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
23/03	Bio-Thera Solutions et Intas Pharmaceuticals concluent un accord exclusif de licence et de commercialisation pour le BAT2506 en Inde	CI

Communiqués

01/04	Accord, Intas, And Bio-Thera File Four IPRs Against Janssen Golimumab Patents	AQ
24/03	Janssen Files BPCIA Complaint Against Bio-Thera And Accord Related To Golimumab Biosimilar	AQ
12/03	Janssen Files BPCIA Complaint Against Bio-Thera And Accord Related To Golimumab Biosimilar	AQ
25/08/25	Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab	AQ
17/07/25	Bio-Thera Solutions Announces FDA Accepts Biologics License Application for BAT2506, a Proposed Biosimilar to Simponi	AQ
15/04/25	Bio-Thera Solutions Presents Clinical Data for multiple products at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting	AQ
13/02/25	Regulatory And Commercial Updates On Bio-Thera's BAT2506 (Golimumab)	AQ
11/02/25	Bio-Thera Solutions Announces Exclusive Commercialization and License Agreement with Intas Pharmaceuticals for BAT2506, a Proposed Biosimilar Referencing Simponi (golimumab), in the United States of America	AQ
10/02/25	Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2506, a Proposed Biosimilar to Simponi, in the European Union	AQ
15/01/25	Bio-Thera Solutions Publishes Phase I Clinical Study Results for BAT4406F, an ADCC-Enhanced Fully Humanized Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorders	AQ
30/12/24	Bio-Thera Solutions Expands Partnership With SteinCares To Market Two Biosimilars In LATAM	AQ
04/11/24	Bio-Thera And Gedeon Richter Reach Exclusive Commercialization Agreement For Ustekinumab Biosimilar	AQ
26/07/24	Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, a Proposed Biosimilar of Keytruda	AQ
12/07/24	Severe Asthma Pipeline 2024 \| Kinaset Therapeutics, Bio-Thera Solutions, CSPC ZhongQi Pharmaceutical Technology, AB Science, GlaxoSmithKline, Oneness Biotech, Biosion, Lanier Biotherapeutics, Kymera	AQ
29/05/24	Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK	AQ
26/03/24	Bio-Thera Solutions Receives IND Clearance from US FDA to Initiate a Phase II Study for BAT8006, an Innovative Antibody Drug Conjugate Targeting Folate Receptor	AQ
21/12/23	Recent Biosimilar Approvals	AQ
16/06/23	Bio-Thera Solutions Expands Partnership with Biomm in Brazil with Addition of BAT2206, a Stelara® Biosimilar	BU
17/04/23	Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	AQ
14/04/23	Bio-Thera Solutions Announces BAT1006 Poster Presentations at the 2023 AACR Annual Meeting	BU
13/03/23	Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8007, an Antibody-Drug Conjugate Targeting Nectin-4 for the Treatment of Advanced Solid Tumors	BU
08/03/23	Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8008, an Antibody-Drug Conjugate Targeting Trop2 for the Treatment of Advanced Solid Tumors	BU
06/03/23	Bio-Thera Solutions Announces First Patient Dosed in Phase 1 Study for BAT8010, an Antibody Drug Conjugate Targeting HER2 for the Treatment of Advanced Solid Tumors	BU
17/01/23	China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra	AQ
16/01/23	China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)	BU